Table 1 –
Baseline demographic and disease characteristics of our 13 MMR-deficient prostate cancers
| Characteristic | MMR-deficient men (N = 13) | MMR-proficient men (N = 114) |
|---|---|---|
| Age at diagnosis (yr) | ||
| Median (Q1–Q3) | 64 (61–70) | 63 (59–69) |
| Race, N (%) | ||
| White | 9 (69) | 99 (87) |
| Presence of any secondary malignancy, N (%) | 3 (23) | 9 (8) |
| Family history of cancer, N (%) | ||
| First-degree relative | 8 (62) | 59 (52) |
| Non–first-degree relative | 5 (38) | 18 (16) |
| Gleason sum at diagnosis, N (%) | ||
| ≤7 | 2 (15) | 30 (26) |
| ≥8 | 10 (77) | 77 (67) |
| Unknown | 1 (8) | 7 (6) |
| Presence of perineural invasion, N (%) | 4 (31) | 68 (60) |
| Presence of variant histology, N (%) | ||
| Ductal/intraductal | 3 (23) | 14 (12) |
| Neuroendocrine | 1 (8) | 0 (0) |
| Tumor stage at diagnosis, N (%) | ||
| T1/T2 | 3 (23) | 36 (32) |
| T3/T4 | 10 (77) | 78 (68) |
| Lymph node stage at diagnosis, N (%) | ||
| N1 | 5 (38) | 15 (13) |
| Metastatic stage at diagnosis, N (%) | ||
| M1 | 6 (46) | 37 (32) |
| Presence of bone metastasis, N (%) | ||
| Bone only | 3 (23) | 34 (30) |
| With visceral metastasis (lung, liver) | 4 (31) | 22 (19) |
| Presence of lung metastasis only, N (%) | 2 (15) | 4 (3) |
| Presence of liver metastasis, N (%) | 2 (15) | 10 (9) |
| Use of standard ADT, N (%) | 13 (100) | 114 (100) |
| Use of abiraterone, N (%) | 3 (23) | 47 (41) |
| Use of enzalutamide, N (%) | 5 (38) | 28 (25) |
| Use of docetaxel, N (%) | 2 (15) | 38 (33) |
| Use of PD-1 inhibitor, N (%) | 4 (31) | 2 (2) |
| PSA at diagnosis (ng/ml) | ||
| Median (Q1–Q3) | 10 (5.4–43) | 13 (5.5–32) |
ADT = androgen deprivation therapy; MMR = mismatch repair; PSA = prostate-specific antigen.
For comparison, we also include baseline characteristics for a group of 114 MMR-proficient men from our somatic sequencing database with full clinical and outcome data.